More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact
The data further confirm the safety and efficacy of the device and add to better understanding of patient selection, researchers say.
Tricuspid-valve transcatheter edge-to-edge repair (TEER) using the TriClip system (Abbott) remains safe and effective in patients with symptomatic severe tricuspid regurgitation (TR), according to new data from the randomized TRILUMINATE Pivotal trial. Moreover, additional insights in a series of nonrandomized patients with more complex anatomies suggest that the device can deliver good results, even in those whose anticipated benefits were more modest.
As reported by TCTMD, the primary endpoint was met for the first 350 randomized patients in the trial, demonstrating a benefit with TEER over medical therapy alone regarding the combination of all-cause death or tricuspid valve surgery, hospitalization for heart failure, and improvement in quality of life according to the Kansas City Cardiomyopathy Questionnaire (KCCQ).
The latest data “strengthen the conclusions” of the original randomized trial, said David H. Adams, MD (Icahn School of Medicine at Mount Sinai, New York, NY), who presented the findings today at TCT 2023. “Our expanded randomized cohort has reinforced our competence that we can significantly reduce tricuspid regurgitation in most patients and that's translating into them feeling better,” he told TCTMD.